Share on StockTwits

Jefferies Group reduced their target price on shares of Alere (NYSE:ALR) from $45.00 to $40.00 in a research note issued on Tuesday. The firm currently has a “buy” rating on the stock. Jefferies Group’s price objective points to a potential upside of 11.42% from the stock’s previous close.

Shares of Alere (NYSE:ALR) traded up 3.31% on Tuesday, hitting $35.90. The stock had a trading volume of 1,552,890 shares. Alere has a one year low of $29.61 and a one year high of $40.80. The stock’s 50-day moving average is $38.13 and its 200-day moving average is $36.34. The company’s market cap is $2.965 billion.

Alere (NYSE:ALR) last issued its quarterly earnings data on Monday, August 4th. The company reported $0.42 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.58 by $0.16. The company had revenue of $738.30 million for the quarter, compared to the consensus estimate of $747.55 million. During the same quarter in the previous year, the company posted $0.64 earnings per share. The company’s revenue for the quarter was down 3.4% on a year-over-year basis. Analysts expect that Alere will post $2.52 EPS for the current fiscal year.

A number of other analysts have also recently weighed in on ALR. Analysts at Leerink Swann cut their price target on shares of Alere from $40.00 to $38.00 in a research note on Tuesday. They now have a “market perform” rating on the stock. Separately, analysts at Canaccord Genuity cut their price target on shares of Alere from $50.00 to $45.00 in a research note on Tuesday. Finally, analysts at Zacks upgraded shares of Alere from an “underperform” rating to a “neutral” rating in a research note on Thursday, July 10th. They now have a $38.70 price target on the stock. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $41.95.

Alere Inc is a provider of point-of-care diagnostics and services. The Company’s products and services help healthcare practitioners make treatment decisions and improve outcomes for individuals living with chronic disease.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.